MoonLake Immunotherapeutics
MLTX
83 hedge funds and large institutions have $2.86B invested in MoonLake Immunotherapeutics in 2023 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 7 closing their positions.
571% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 7
400% more funds holding in top 10
Funds holding in top 10: 2 → 10 (+8)
239% more capital invested
Capital invested by funds: $843M → $2.86B (+$2.02B)
213% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 8
93% more funds holding
Funds holding: 43 → 83 (+40)
27.75% more ownership
Funds ownership: 100.69% → 128.44% (+28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$78.1M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$46.4M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$33.6M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$30.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$24.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.98M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.95M |
| 4 |
Axa
Paris,
France
|
-$3.94M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.45M |
MLTX Hedge Fund Activity: Q2 2023 in Review
83 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2023, worth a combined $2.86B — up 239% from $843M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new MLTX positions and 7 closed out — a net gain of 40 holders — while 25 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $78.1M. The largest seller was Citadel Advisors, cutting an estimated $24.3M.
- 83 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2023, up from 43 in Q1 2023.
- Funds reported $2.86B of MoonLake Immunotherapeutics stock for Q2 2023, up 239% quarter-over-quarter.
- 47 funds opened new MoonLake Immunotherapeutics positions in Q2 2023 and 7 closed out, a net change of +40 holders.
- The largest MoonLake Immunotherapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $78.1M added.
- The largest MoonLake Immunotherapeutics seller in Q2 2023 was Citadel Advisors, an estimated $24.3M sold.
Based on aggregated 13F filings for Q2 2023.